DARATUMUMAB SHOWS REMARKABLE BENEFIT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE POLLUX STUDY
Dr Meletios A Dimopoulos (Abstract LB2238):
IMMUNOTHERAPY DELIVERED BY BLINATUMOMAB IMPROVES SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKAEMIA PATIENTS (TOWER-Study)
Dr Max S Topp (Abstract S149):
Comment Prof. Dr. med. Markus Manz, Klinikdirektor,
Klinik für Hämatologie, UniversitätsSpital Zürich:
THE ROOT OF EVIL: PRE-LEUKEMIC CLONES THAT SURVIVE CHEMOTHERAPY ARE LINKED TO A HIGHER RISK OF LEUKEMIA RECURRENCE
Dr Klaus Metzeler (Abstract S146):
STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL
Dr Johan Richter (Abstract S145):
MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH NOACs OR VKAs IN REAL-LIFE: CLINICAL PRESENTATION, MANAGEMENT AND OUTCOME
Dr Laura Franco (Abstract S139):
RESTORING EFFECTIVE ANTI-TUMOR RESPONSE IN HODGKIN LYMPHOMA WITH NIVOLUMAB
Dr Anas Younes (Abstract S793):
EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES
Dr Jeffrey Jones (Abstract S429):
A NEW FORM OF INHERITED THROMBOCYTOPENIA (ETV6-RELATED THROMBOCYTOPENIA, ETV6- RT): NEVER JUDGE A BOOK BY ITS COVER!
Dr Federica Melazzini (Abstract S148):